Billions of patients are living without answers or effective treatments for neurological and psychiatric conditions because the brain remains one of the most complex frontiers in medicine. Beacon’s AI-powered technology is bringing precision neuroscience to clinical trials and accelerating drug development for unmet medical needs, so life-changing treatments can reach patients faster.
Unlocking the Power of Sleep:
A Window into the Central Nervous System
Sleep provides a stable, naturally occurring state in which brain activity can be measured with unparalleled consistency using EEG technology, enabling the identification of novel biomarkers, treatment effects, and patient stratification. With quantitative sleep analysis, we make it possible to assess a wide range of indications faster, more accurately, and with less participant and site burden than traditional methods.
Our Platform:
An End-to-End Solution for EEG Biomarkers in Clinical Research
Clinical-Grade Sleep EEG Capture
Our FDA-cleared headband collects high-fidelity sleep EEG at home or in clinical settings. Data is securely uploaded to the Beacon Platform, where AI models trained on 200,000+ hours of EEG data characterize brain function across individuals and populations.
Low-Latency Event Monitoring
Through Beacon’s analytics software, clinical development teams can assess compliance across trial sites, identify treatment response, and drill-down into relevant patient cohorts.
Full-Service Clinical Trial Support
Our Clinical Study Operations and Scientific Services teams manage device setup, software integration, data quality, and reporting, bringing deep expertise across every stage of drug development.
Our Impact:
Biomarkers that Transform Drug Development and Patient Care
Identify Dose-Dependent Drug Effects
Detect drug effects that traditional measurement methods may overlook, driving differentiation and deeper insight. Our pharmacodynamic biomarkers can inform dose selection by demonstrating how patients respond to different levels of treatment.
Characterize Patient Populations
Identify biomarkers that help diagnose or stratify target populations, whether within clinical trials, real-world settings, or as a comparison between the two. Leverage sleep as a primary, secondary, or exploratory endpoint for a more precise trial design.
Expand Labeling Language
Use quantitative endpoints as meaningful, and in some cases required, evidence to support a desired claim and expand labeling language. Demonstrated sleep improvement can support both clinical relevance and commercial differentiation.
Track Disease Progression Early
Measure cognitive trajectories in conditions where traditional outcomes may take years—or decades—to observe. Our tools enable earlier insights into disease progression and support a deeper understanding of neurological and psychiatric conditions, helping drive timely and targeted intervention.
Where We Deliver Value
From discovery to clinical practice, Beacon Biosignals supports every stage of therapeutic development. Our platform helps teams extract meaningful insights from EEG data, optimize trials with objective sleep endpoints, and differentiate treatments through real-world evidence.
01.
Translational Research
Leverage existing EEG data to uncover disease mechanisms, inform pharmacokinetic (PK) and pharmacodynamic (PD) analysis, and characterize patients.
02.
Clinical Trial Optimization
Demonstrate target engagement, guide dose selection, and deploy quantitative endpoints to improve probability of trial and regulatory success.
03.
Clinical
Practice
Enhance evidence of treatment efficacy and provide data to enable label expansion for new therapeutic applications.
News & Resources
What's New at Beacon
Check out our latest press releases, announcements, partnerships, and more.
Press Release
Beacon Biosignals Completes Strategic Transaction to Acquire CleveMed
Beacon Biosignals
Apr 21, 2025
Press Release
Beacon Biosignals Reports Novel Sleep EEG Results from Multiple Industry Collaborations at the American Epilepsy Society Annual Meeting
Beacon Biosignals
Dec 13, 2024
Press Release
FDA Authorizes Beacon’s Dreem 3S as First Sleep Wearable with Predetermined Change Control Plan, Paving the Way for Continuous Algorithm Enhancements in Sleep Monitoring
Beacon Biosignals
Dec 3, 2024